Kevin Phillips
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kevin Phillips has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- S. Lalchandani
St Munchin’s Regional Maternity Hospital
2 shared publications - Alison McDonald
Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK
1 shared publication - Andrew J Baxter
The Jessop Wing, The Royal Hallamshire Hospital, Sheffield, S10 2SF, UK
1 shared publication - Angela Hyde
Royal College of Obstetricians and Gynaecologists Women’s Network, Regent’s Park, London, NW1 4RG, UK
1 shared publication - Graham Scotland
Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
1 shared publication - Jed Hawe
Countess of Chester Hospital NHS Foundation Trust, Countess of Chester Health Park, Liverpool Road, Chester, CH2 1UL, UK
1 shared publication
Latest Publications
- 27 June 2018
- Published by Springer Nature
- p. 207-211
Abdominal Hysterectomy
- Open Access
- 24 January 2018
- Published by Springer Nature in Trials
- Vol. 19 (1) , 63
HEALTH: laparoscopic supracervical hysterectomy versus second-generation endometrial ablation for the treatment of heavy menstrual bleeding: study protocol for a randomised controlled trial
Heavy menstrual bleeding (HMB) is a common problem affecting approximately 1.5 million women in England and Wales with a major impact on their physical, emotional, social and material quality of life. It is the fourth most common reason why women attend gynaecology outpatient clinics and accounts for one-fifth of all gynaecology outpatient referrals. Initial treatment in primary care is medical - either by means of oral or injected medication or the levonorgestrel-intrauterine system (Mirena®). If medical treatment fails then surgical treatment can be offered, either endometrial ablation (EA), which destroys the lining of the cavity of the uterus (endometrium), or hysterectomy, i.e. surgical removal of the uterus. While effective, conventional hysterectomy is invasive and carries a risk of complications due to injury to other pelvic structures. The procedure can be simplified and complications minimised by undertaking a ‘supracervical’ hysterectomy where the cervix is left in situ and only the body of the uterus removed. Recent advances in endoscopic technologies have facilitated increased use of laparoscopic supracervical hysterectomy (LASH) which can be performed as a day-case procedure and is relatively easy for the surgeon to learn. HEALTH (Hysterectomy or Endometrial AbLation Trial for Heavy menstrual bleeding) aims to address the question ‘Is LASH superior to second generation EA for the treatment of HMB in terms of clinical and cost effectiveness?’ Women aged < 50 years, with HMB, in whom medical treatment has failed and who are eligible for EA will be considered for trial entry. We aim to recruit women from approximately 30 active secondary care centres in the UK NHS who carry out both surgical procedures. All women who consent will complete a diary of pain symptoms from day 1 to day 14 after surgery, postal questionnaires at six weeks and six months after surgery and 15 months post randomisation. Healthcare utilisation questions will also be completed at the six-week, six-month and 15-month time-points. Measuring the comparative effectiveness of LASH vs EA will provide the robust evidence required to determine whether the new technique should be adopted widely in the NHS. International Standard Randomised Controlled Trials, ISRCTN49013893 . Registered on 28 January 2014.
- 24 January 2018
- Published by Springer Nature in Trials
- Vol. 19 (1) , 63
Open AccessHEALTH: laparoscopic supracervical hysterectomy versus second-generation endometrial ablation for the treatment of heavy menstrual bleeding: study protocol for a randomised controlled trial
Heavy menstrual bleeding (HMB) is a common problem affecting approximately 1.5 million women in England and Wales with a major impact on their physical, emotional, social and material quality of life. It is the fourth most common reason why women attend gynaecology outpatient clinics and accounts for one-fifth of all gynaecology outpatient referrals. Initial treatment in primary care is medical - either by means of oral or injected medication or the levonorgestrel-intrauterine system (Mirena®). If medical treatment fails then surgical treatment can be offered, either endometrial ablation (EA), which destroys the lining of the cavity of the uterus (endometrium), or hysterectomy, i.e. surgical removal of the uterus. While effective, conventional hysterectomy is invasive and carries a risk of complications due to injury to other pelvic structures. The procedure can be simplified and complications minimised by undertaking a ‘supracervical’ hysterectomy where the cervix is left in situ and only the body of the uterus removed. Recent advances in endoscopic technologies have facilitated increased use of laparoscopic supracervical hysterectomy (LASH) which can be performed as a day-case procedure and is relatively easy for the surgeon to learn. HEALTH (Hysterectomy or Endometrial AbLation Trial for Heavy menstrual bleeding) aims to address the question ‘Is LASH superior to second generation EA for the treatment of HMB in terms of clinical and cost effectiveness?’ Women aged < 50 years, with HMB, in whom medical treatment has failed and who are eligible for EA will be considered for trial entry. We aim to recruit women from approximately 30 active secondary care centres in the UK NHS who carry out both surgical procedures. All women who consent will complete a diary of pain symptoms from day 1 to day 14 after surgery, postal questionnaires at six weeks and six months after surgery and 15 months post randomisation. Healthcare utilisation questions will also be completed at the six-week, six-month and 15-month time-points. Measuring the comparative effectiveness of LASH vs EA will provide the robust evidence required to determine whether the new technique should be adopted widely in the NHS. International Standard Randomised Controlled Trials, ISRCTN49013893 . Registered on 28 January 2014.
- 31 August 2005
- Published by Springer Nature in Gynecological Surgery
- Vol. 2 (4) , 245-249
Laparoscopic entry technique—a survey of practices of consultant gynaecologists
- 31 August 2005
- Published by Springer Nature in Gynecological Surgery
- Vol. 2 (4) , 245-249
Laparoscopic entry technique—a survey of practices of consultant gynaecologists
- 17 August 2005
- Published by Springer Nature in Gynecological Surgery
- Vol. 2 (4) , 255-258
Is helium thermal coagulator therapy for the treatment of women with minimal to moderate endometriosis cost-effective? A prospective randomised controlled trial
- 17 August 2005
- Published by Springer Nature in Gynecological Surgery
- Vol. 2 (4) , 255-258
Is helium thermal coagulator therapy for the treatment of women with minimal to moderate endometriosis cost-effective? A prospective randomised controlled trial